Newleos Therapeutics Appoints Timothy Noyes as President and Chief Executive Officer October 22, 2025
Newleos Therapeutics CEO David Donabedian Recognized by Goldman Sachs as One of the Most Exceptional Entrepreneurs at the 2025 Builders and Innovators Summit October 16, 2025
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer October 9, 2025
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease October 3, 2025
